Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Falster

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
International Journal of Cancer|March 19, 2014
Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006Marina T van Leeuwen, Jennifer J Turner, David J Joske, et al.
British Journal of Clinical Pharmacology|September 3, 2024
Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
Annals of Surgery|December 20, 2022
Long-term Mortality and Reintervention After Endovascular and Open Abdominal Aortic Aneurysm Repairs in Australia, Germany, and the United StatesJialin Mao, Christian-Alexander Behrendt, Michael O Falster, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, AustraliaJuliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, et al.
Diabetes, Obesity & Metabolism|November 8, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
European Journal of Clinical Pharmacology|June 30, 2025
Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular riskJuliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, et al.
Drug and Alcohol Dependence|May 5, 2015
The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort studyClaire M Vajdic, Sadaf Marashi Pour, Sadaf Marashi Pour, et al.
Diabetes Research and Clinical Practice|May 10, 2025
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based studyJialing Lin, Tamara Y Milder, Claire T Deakin, et al.
BMJ Open|October 15, 2025
Patterns of follow-up testing of abnormal eGFR and UACR for the detection of chronic kidney disease in Australian primary care: analysis of a national general practice datasetAngela Kathy Li, Sradha Kotwal, Hannah Wallace, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
International Journal of Cancer|March 19, 2014
Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006Marina T van Leeuwen, Jennifer J Turner, David J Joske, et al.
British Journal of Clinical Pharmacology|September 3, 2024
Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
Annals of Surgery|December 20, 2022
Long-term Mortality and Reintervention After Endovascular and Open Abdominal Aortic Aneurysm Repairs in Australia, Germany, and the United StatesJialin Mao, Christian-Alexander Behrendt, Michael O Falster, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, AustraliaJuliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, et al.
Diabetes, Obesity & Metabolism|November 8, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
European Journal of Clinical Pharmacology|June 30, 2025
Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular riskJuliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, et al.
Drug and Alcohol Dependence|May 5, 2015
The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort studyClaire M Vajdic, Sadaf Marashi Pour, Sadaf Marashi Pour, et al.
Diabetes Research and Clinical Practice|May 10, 2025
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based studyJialing Lin, Tamara Y Milder, Claire T Deakin, et al.
BMJ Open|October 15, 2025
Patterns of follow-up testing of abnormal eGFR and UACR for the detection of chronic kidney disease in Australian primary care: analysis of a national general practice datasetAngela Kathy Li, Sradha Kotwal, Hannah Wallace, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
Pageof 8